CALCA and early-onset autosomal dominant Alzheimer disease: Recent studies have brought attention to the activation of the calcitonin receptor through the calcitonin gene-related peptide (CGRP), revealing the potential therapeutic effects of calcitonin in Alzheimer’s disease (AD) and metabolic syndrome (MetS).